{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:32:36Z","timestamp":1793914356229,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770004"],"award-info":[{"award-number":["81770004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2018ZX09201-013"],"award-info":[{"award-number":["2018ZX09201-013"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jgar.2021.04.013","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T13:25:56Z","timestamp":1620739556000},"page":"380-389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"25","author":[{"given":"Huan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.04.013_bib0001","series-title":"Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment","year":"2013"},{"key":"10.1016\/j.jgar.2021.04.013_bib0002","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jemermed.2014.12.001","article-title":"Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital","volume":"48","author":"Pollack","year":"2015","journal-title":"J Emerg Med"},{"key":"10.1016\/j.jgar.2021.04.013_bib0003","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1080\/14656566.2019.1617851","article-title":"Novel developments in the treatment of acute bacterial skin and skin structure infections","volume":"20","author":"Jaffa","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jgar.2021.04.013_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143276","article-title":"Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact","volume":"10","author":"Kaye","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jgar.2021.04.013_bib0005","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1198-743X(16)30095-7","article-title":"Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections","volume":"22","author":"Russo","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.04.013_bib0006","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/j.jemermed.2012.11.050","article-title":"Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines","volume":"44","author":"Moran","year":"2013","journal-title":"J Emerg Med"},{"key":"10.1016\/j.jgar.2021.04.013_bib0007","first-page":"409","article-title":"Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections","volume":"13","author":"Wu","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2021.04.013_bib0008","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2146\/ajhp110572","article-title":"Oritavancin: an investigational lipoglycopeptide antibiotic","volume":"70","author":"Karaoui","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jgar.2021.04.013_bib0009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/01.NPR.0000544995.21102.7f","article-title":"Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections","volume":"43","author":"Bell","year":"2018","journal-title":"Nurse Pract"},{"key":"10.1016\/j.jgar.2021.04.013_bib0010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.013_bib0011","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2021.04.013_bib0012","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1128\/AAC.00029-11","article-title":"SIMPLIFI Study Team. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial","volume":"55","author":"Dunbar","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.013_bib0013","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-016-0145-7","article-title":"Single-dose oritavancin compared to standard of care IV antibiotics for acute bacterial skin and skin structure infection in the outpatient setting: a retrospective real-world study","volume":"6","author":"Anastasio","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.jgar.2021.04.013_bib0014","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s40801-020-00201-y","article-title":"Early directed oritavancin therapy in the emergency department may lead to hospital avoidance compared to standard treatment for acute bacterial skin and skin structure infections: a real-world retrospective analysis","volume":"7","author":"Helton","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.jgar.2021.04.013_bib0015","doi-asserted-by":"crossref","first-page":"ofz475","DOI":"10.1093\/ofid\/ofz475","article-title":"Comparisons of 30-day admission and 30-day total healthcare costs between patients who were treated with oritavancin or vancomycin for a skin infection in the outpatient setting","volume":"6","author":"Lodise","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2021.04.013_bib0016","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s40801-020-00196-6","article-title":"Expediting discharge in hospitalized, adult patients with skin and soft tissue infections who received empiric vancomycin therapy with oritavancin: description of findings from an institutional pathway","volume":"7","author":"Whittaker","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.jgar.2021.04.013_bib0017","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/phar.2389","article-title":"Advantages of outpatient treatment with long-acting lipoglycopeptides for serious Gram-positive infections: a review","volume":"40","author":"Krsak","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.jgar.2021.04.013_bib0018","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s40801-020-00189-5","article-title":"Real-world evidence studies of oritavancin use in Gram-positive infections augment randomized controlled trials to address clinical and economic outcomes","volume":"7","author":"Redell","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.jgar.2021.04.013_bib0019","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1517\/13543784.15.4.417","article-title":"Oritavancin\u2014an investigational glycopeptide antibiotic","volume":"15","author":"Ward","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jgar.2021.04.013_bib0020","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2021.04.013_bib0021","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle\u2013Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jgar.2021.04.013_bib0022","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cmi.2017.08.028","article-title":"Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis","volume":"24","author":"Agarwal","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.04.013_bib0023","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1185\/03007995.2015.1058248","article-title":"Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis","volume":"31","author":"Thom","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jgar.2021.04.013_bib0024","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40121-016-0119-9","article-title":"Single-dose oritavancin treatment of acute bacterial skin and skin structure infections: SOLO trial efficacy by Eron severity and management setting","volume":"5","author":"Deck","year":"2016","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2021.04.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01968-16","article-title":"Effects of oritavancin on coagulation tests in the clinical laboratory","volume":"61","author":"Belley","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.013_bib0026","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1177\/0091270009355449","article-title":"Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study","volume":"50","author":"Darpo","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2021.04.013_bib0027","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/cpdd.268","article-title":"Electrocardiographic effects of a supratherapeutic dose of oritavancin","volume":"5","author":"Mason","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jgar.2021.04.013_bib0028","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1128\/AAC.00176-15","article-title":"Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials","volume":"59","author":"Rubino","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.013_bib0029","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41426-018-0205-z","article-title":"Emergence of a dalbavancin induced glycopeptide\/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis","volume":"7","author":"Kussmann","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.jgar.2021.04.013_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.04.013_bib0031","first-page":"752","article-title":"Use of oritavancin in moderate-to-severe ABSSSI patients requiring IV antibiotics: a U.S. payer budget impact analysis","volume":"22","author":"Jensen","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jgar.2021.04.013_bib0032","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clinthera.2015.11.014","article-title":"Economic impact of oritavancin for the treatment of acute bacterial skin and skin structure infections in the emergency department or observation setting: cost savings associated with avoidable hospitalizations","volume":"38","author":"Lodise","year":"2016","journal-title":"Clin Ther"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521001120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521001120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:59:05Z","timestamp":1761991145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521001120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":32,"alternative-id":["S2213716521001120"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.04.013","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}